COMPANY PROFILE · /aqemia
A

Aqemia

<cite index="1-6,1-7">Aqemia combines generative AI with deep physics simulations to revolutionize drug discovery at the molecular level. Founded in 2019, it has raised over $100 million and, in 2025, expanded its operations to London as it moves closer to launching clinical trials for its AI-discovered drug candidates.</cite> <cite index="1-5">Reduces the energy consumption of AI training by up to 80%, enabling scalable and eco-friendly AI deployments.</cite>

aqemia.ai· Paris, France· founded 2019reported
Fresh · 3d ago
Latest valuation
Annual Recurring Revenue
Headcount
Funding total
$100M+
OVERVIEW

<cite index="1-9">A $38 million funding round in 2024 and a grant from the France 2030 plan.</cite> Moving toward clinical trials with AI-discovered drug candidates demonstrates material product progress.

Status
active
Tier
master-list
Profitability
Pricing
enterprise
FUNDING HISTORY · 0
No funding rounds on file.
PRODUCTS · 0

No products catalogued yet. Press Refresh above to ask the research agent.

TEAM · 0 key people

No people linked.

SOURCES · 0 cited

No citations stored yet. Run the research agent to attach per-claim sources.